Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. reports developments as a pharmaceutical company developing proprietary small-molecule drug candidates for diseases with high unmet medical needs. Its pipeline targets CB1 and CB2 receptors and includes INM-901 for Alzheimer's disease, along with ocular and dermatological programs.
Recurring updates cover financial results, business progress, preclinical and regulatory disclosures, shareholder voting matters, capital actions, Nasdaq listing compliance, and changes affecting BayMedica, its wholly owned subsidiary historically associated with rare cannabinoid commercial activities.
InMed Pharmaceuticals reported its second quarter fiscal 2021 financial results, ending December 31, 2020. The company achieved critical milestones in its drug development, particularly for INM-755 aimed at Epidermolysis Bullosa, with upcoming Phase 2 trials planned. It secured a worldwide license for ocular drug delivery technology, MiDROPS®, enhancing its research pipeline. Financially, InMed raised about $12.5 million through recent offerings and recorded a net loss of $2.2 million in Q2 2021, an improvement from $2.5 million in Q2 2020.
InMed Pharmaceuticals Inc. (NASDAQ: INM) will report its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on February 11, 2021. A conference call and webcast will occur at 8:30 AM Pacific Time. The company is focused on developing cannabinoid-based medications, particularly targeting the therapeutic benefits of cannabinol (CBN). Full financial statements will be accessible on their website and regulatory authorities after the announcement.
InMed Pharmaceuticals Inc. (NASDAQ: INM), a clinical-stage pharmaceutical company, is set to report its financial results for Q2 of fiscal year 2021 on February 11, 2021. The company focuses on developing cannabinoid-based medications, specifically cannabinol (CBN) for diseases with high unmet medical needs. A conference call and webcast will take place on the same day at 8:30 AM PT with details available on their website. InMed emphasizes its commitment to delivering therapeutic alternatives while navigating the uncertainties inherent in clinical development.
InMed Pharmaceuticals Inc. announced a private placement to raise approximately US$4.5 million, issuing units at US$4.25 per share. Each unit consists of one common share and 0.66 warrants with an exercise price of US$4.85. The expected net proceeds are about US$4.0 million, intended for working capital. The offering is expected to close around February 12, 2021, pending regulatory approval. Roth Capital Partners is the placement agent, and InMed will file a registration statement for resales within 30 days post-closing.
InMed Pharmaceuticals Inc. announced a private placement to raise approximately US$4.5 million at US$4.25 per unit, with each unit consisting of one common share and 0.66 warrant. The exercise price for the warrants is set at US$4.85, with an expected close date of February 12, 2021. After fees, net proceeds are anticipated to be around US$4.0 million for working capital. Roth Capital Partners acted as the exclusive placement agent. The announcement includes forward-looking statements regarding regulatory approvals and the potential success of its cannabinoid-based therapies.
InMed Pharmaceuticals Inc. (NASDAQ:INM) announced participation in the virtual 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe from January 19-21, 2021. Key executives, including Michael Woudenberg, Karen Long, and Prof. Mauro Maccarrone, will share insights on cannabinoid therapeutics. Woudenberg will discuss the comparison of whole plant and synthetic cannabinoids, while Long will focus on drug approval processes. Maccarrone will address endocannabinoid signaling in his lecture. CEO Eric A. Adams highlighted the company's progress in therapeutic development.
InMed Pharmaceuticals Inc. (NASDAQ: INM, TSX: IN) announced promising top-line results from its 755-102-HV Phase 1 clinical trial evaluating INM-755 cream for treating epidermolysis bullosa. The trial, involving 8 healthy volunteers, demonstrated that the cream was safe and well-tolerated, with no significant adverse effects noted. Notably, the cream did not impede normal wound healing. Following this success, InMed is preparing to file regulatory applications for a Phase 2 efficacy and safety study in multiple countries within the first half of 2021.
InMed Pharmaceuticals (NASDAQ: INM) will participate in several virtual investor and partnering conferences in January 2021. Key events include the H.C. Wainwright BioConnect Conference from January 11-14, where a presentation by CEO Eric A. Adams will be available on demand. Additionally, the BIO Partnering at JPM will occur January 11-15, with registration options available. The Edison Open House: Global Healthcare 2021 is set for January 26-28. InMed focuses on developing cannabinoid-based medications for diseases with significant unmet medical needs.
InMed Pharmaceuticals has secured an exclusive worldwide license from EyeCRO for its MiDROPS® eyedrop delivery technology, enhancing the development of INM-088 for treating ocular diseases, including glaucoma. This technology aims to effectively administer cannabinoids to the eye. InMed's preliminary studies show that MiDROPS® delivers sustained CBN levels more effectively than other formulations. The agreement includes milestone payments and royalties to EyeCRO. InMed plans to initiate IND-enabling toxicology studies for INM-088 in 2021.
InMed Pharmaceuticals (NASDAQ: INM) has announced positive top-line results from its Phase 1 clinical trial, Study 101, for INM-755, a cannabinol (CBN) cream targeting epidermolysis bullosa (EB). Conducted with 22 healthy volunteers, the study showed that INM-755 was safe and well-tolerated, with no serious adverse effects or withdrawals. Local skin responses were minimal and resolved without intervention. The next Phase 1 trial, Study 102, investigating the effect of INM-755 on small epidermal wounds, is expected to report results in early 2021.